Ibrahim Aldoss, MD, is an associate professor in the Division of Leukemia in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope

Elias Jabbour, MD, is a professor in the Department of Leukemia of the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center.

Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss FDA approval of ponatinib in newly diagnosed patients with Philadelphia chromosome–positive ALL.

FDA Approval of Ponatinib for ALL

Hematologic Oncology

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Treatment Updates in Ph+ Acute Lymphoblastic Leukemia

OncLive News Network®

City of Hope

Cancer Centers

Partner

The University of Texas MD Anderson Cancer Center

Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss the impact of the FDA approval of ponatinib for the treatment of newly diagnosed patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.


The Impact of the Ponatinib FDA Approval in Newly Diagnosed Ph+ ALL